MRG003 With Gemcitabine for Second-line Advanced PDAC

Clinical trial NCT07685470 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07685470
Sponsor: Peking Union Medical College Hospital
Status: NOT_YET_RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Pancreatic Ductal Adenocarcinoma (PDAC)Second Line Treatment

Start date: 2026-06-08
Primary completion: 2028-05-07
Enrollment: 30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.